Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (313)	2/25/1999 9:36:00 PM
From: tuck	Read Replies (2) \| Respond to of 2515

Quiet Won, I was being a bit facetious there. ImClone does not have the baggage of this "cure for cancer" hype that characterizes ENMD, making the latter a risky investment even for a biotech. When will the hype die down? It may be a while, but eventually those that were fooled by it will bail. We know that many antiangiogenic (sp?) compounds are under development that may be easier to produce and easier to target. ImClone's technology also meets those two standards with a different approach that seems to work very well. I like it a lot better than ENMD's technology, and I expect that ENMD will soon be cheaper than IMCL. Cheers, Tuck